Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alterity TherapeuticsASX:ATH -5.08%25 3-Year EBITDA Growth Rate is 32.80% as of Mar. 2026, which is 173% above its 10-year median of 12.00. GuruFocus rates ASX:ATH with a GF Score™ of 25/100. Among 1,136 Biotechnology companies, Alterity Therapeutics ranks better than 70.69% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 32.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 28.70% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 17.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Alterity Therapeutics was 34.90% per year. The lowest was -63.80% per year. And the median was 12.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Alterity Therapeutics 3-Year EBITDA Growth Rate Related Terms
ASX:ATH vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Alterity Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alterity Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Alterity Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 32.80% mean?
Alterity Therapeutics (ASX:ATH) has a 3-Year EBITDA Growth Rate of 32.80% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Alterity Therapeutics and its competitors. This is 173% above median its historical median of 12.00. According to the industry distribution chart, Alterity Therapeutics ranks #333 out of 1136 companies in the Biotechnology industry, placing it in the top 29.3%.
Is Alterity Therapeutics' 3-Year EBITDA Growth Rate too high?
Alterity Therapeutics' current 3-Year EBITDA Growth Rate of 32.80% is 173% above median its 10-year median of 12.00. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Alterity Therapeutics' value of 32.80% is 120.9% above this industry median. Based on the distribution chart, Alterity Therapeutics ranks #333 out of 1136 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Alterity Therapeutics has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alterity Therapeutics ranks #333 out of 1136 companies for 3-Year EBITDA Growth Rate. This puts Alterity Therapeutics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. Alterity Therapeutics' value of 32.80% is 120.9% above this benchmark. While the company's 10-year median is 12.00 vs. the industry median of 14.85, Alterity Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alterity Therapeutics's current 3-Year EBITDA Growth Rate of 32.80% is 120.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Alterity Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alterity Therapeutics's current 3-Year EBITDA Growth Rate is 32.80%, which is 173% above median its own 10-year median of 12.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (ASX:ATH) has a current 3-Year EBITDA Growth Rate of 32.80%. The current 3-Year EBITDA Growth Rate is 32.80%, which is 173% above median its 10-year median of 12.00 and 120.9% above the Biotechnology industry median of 14.85. Alterity Therapeutics' overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Alterity Therapeutics (ASX:ATH), the current 3-Year EBITDA Growth Rate is 32.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
25GF Score
Get the complete analysis for ASX:ATH
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ATH has been successfully added to your 
